Clinical trial
A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric…
NCT00192088 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00192088 |
|---|---|
| Title | A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma |
| Official title | Open-Label Single-Arm Phase II Study of ALIMTA in Combination With Oxaliplatin as First-Line Therapy in Advanced Gastric Carcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Gastric Carcinoma |
| Intervention type | Drug |
| Interventions | pemetrexed, oxaliplatin |
| Enrollment | 43 |
| Start date | May 1, 2004 |
| Completion | May 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: